You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 54.234.0.0/16 has been blocked (disabled) by ‪JJMC89‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 05:36, 2 January 2025.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Jon Kolbert‬. The reason given is Open proxy/Webhost: See the help page if you are affected .
- Start of block: 05:40, 21 February 2024
- Expiry of block: 05:40, 21 February 2029
Your current IP address is 54.234.187.160. The blocked range is 54.234.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Short description|Pharmaceutical company))
((More citations needed|date=October 2023))
((coord|40.678631|N|78.243038|W|type:city_region:US|display=title))
((Infobox company
| name = Intercept Pharmaceuticals
| logo = InterceptlogoV2.jpg
| logo_size = 200px
| traded_as = ((NASDAQ was|ICPT)) (2012-23)
| foundation = 2002
| fate = Acquired by [[Alfasigma]]
| location_city = [[Morristown, New Jersey]]
| location_country = [[United States]]<ref>((cite web |title=Contact Us |url=https://interceptpharma.com/contact-us/ |website=Intercept Pharmaceuticals |access-date=13 April 2022))</ref>
| key_people = Jerome Durso<br /><small>([[President (corporate title)|President]] and [[Chief Executive Officer|CEO]])</small><br />Paolo Fundarò<br /><small>(Chairman of the Board of Directors)</small>
| industry = [[Biotechnology]]
| website = ((URL|http://www.interceptpharma.com))
| revenue = ((Increase)) $250.2 Million(2019)<ref>((Cite web|url=https://www.macrotrends.net/stocks/charts/ICPT/intercept-pharmaceuticals/revenue|title = Intercept Pharmaceuticals Revenue 2011-2021 &#124; ICPT))</ref>
))
'''Intercept Pharmaceuticals, Inc.''' is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as [[primary biliary cirrhosis]] (PBC) now called primary biliary cholangitis, [[non-alcoholic fatty liver disease]] (or [[non-alcoholic steatohepatitis]], NASH), [[cirrhosis]], [[portal hypertension]], [[primary sclerosing cholangitis]] and also the intestinal disorder, [[bile acid diarrhea]].

==Products==
The company's lead product is [[obeticholic acid]], OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva.  OCA is a potent first-in-class [[farnesoid X receptor]] (FXR) agonist.  As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.  It is in phase III studies for non-alcoholic steatohepatitis (NASH) and phase II studies for primary sclerosing cholangitis.

Other products in the development pipeline include INT-767, a dual FXR/[[TGR5]] agonist, and INT-777, a TGR5 agonist.

On June 29, 2020, the company released a statement announcing that FDA had rejected its lead product [[obeticholic acid]], OCA, because FDA officials had determined that "the predicted benefit of the drug does not sufficiently outweigh the predicted risks".<ref>((cite web| url = https://www.statnews.com/2020/06/29/fda-rejects-intercept-pharmas-drug-for-nash/| title = FDA rejects Intercept Pharma's drug for fatty liver disease| date = 29 June 2020))</ref>

==Initial public offering and stock history==
Intercept trades on the [[NASDAQ]] exchange under the ticker symbol ICPT.  The initial public offering of the stock on October 16, 2012 was at $15.<ref>((Cite news|url=http://seekingalpha.com/article/922511-intercept-pharmaceuticals-strong-biopharmaceutical-ipo|publisher=Seeking Alpha|date=October 14, 2012|access-date=2014-03-21|title=Intercept Pharmaceuticals: Strong Biopharmaceutical IPO))</ref>  A follow-on public offering at $33 took place on June 24, 2013.

On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by [[National Institute of Diabetes and Digestive and Kidney Diseases|NIDDK]].<ref>((cite web|title=The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)|url=http://clinicaltrial.gov/ct2/show/NCT01265498.|url-status=dead|archive-url=https://web.archive.org/web/20140110085154/http://clinicaltrial.gov/ct2/show/NCT01265498.|archive-date=2014-01-10))</ref><ref>((cite web|last=Intercept Pharma|title=Press release: Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology|url=http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=818119|access-date=January 9, 2014|archive-url=https://web.archive.org/web/20141129035157/http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=818119|archive-date=November 29, 2014|url-status=dead))</ref>  The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.

In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum [[alkaline phosphatase]], a [[biomarker]] for the disease.<ref>((cite web|last=Intercept Pharma|title=Press release: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results|url=http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=833072|access-date=March 27, 2014|archive-url=https://web.archive.org/web/20140326071523/http://ir.interceptpharma.com/releasedetail.cfm?ReleaseID=833072|archive-date=March 26, 2014|url-status=dead))</ref>  These results were presented at an international liver meeting in April 2014.<ref>((cite web|title=Intercept's liver disease drug proves highly effective in study.
|url=https://www.reuters.com/article/us-liver-intercept-idUSBREA3B04220140412|publisher=Reuters |date=April 12, 2014|access-date=April 14, 2014))</ref>

As of 31 December 2014, the company has 136 employees.<ref>((cite web|last=Intercept Pharmaceuticals|title=Form 10-k: Annual report 2014|url=http://ir.interceptpharma.com/common/download/sec.cfm?CompanyID=AMDA-1AUOV7&FID=1144204-15-13338&CIK=1270073|access-date=October 2, 2015))</ref>

In 2023, Intercept Pharmaceuticals was acquired by Italian [[Alfasigma]] S.p.A for $19.00 per share in cash (approximately $800 million).<ref>((Cite web |date=2023-09-26 |title=Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases |url=https://finance.yahoo.com/news/alfasigma-acquire-intercept-pharmaceuticals-19-120000209.html |access-date=2023-09-26 |website=Yahoo Finance |language=en-US))</ref><ref>((Cite web |title=Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs |url=https://www.biospace.com/article/madrigal-pursues-500m-public-offering-with-nash-market-up-for-grabs/ |quote=On Tuesday, still reeling from the rejection and left with no other advanced assets, Intercept agreed to be acquired by Italian pharma Alfasigma S.p.A for $800 million.))</ref><ref>((Cite web|url=https://finance.yahoo.com/news/alfasigma-completes-acquisition-intercept-pharmaceuticals-141300657.html|title=Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.|work=Yahoo! Finance|access-date=2024-01-07|language=en))</ref>

==References==
((Reflist))

==External links==
* ((Official website))

((Pharmaceutical companies of the United States))
((Authority control))

[[Category:2023 mergers and acquisitions]]
[[Category:Companies formerly listed on the Nasdaq]]
[[Category:Biotechnology companies of the United States]]
[[Category:Pharmaceutical companies based in New Jersey]]
[[Category:Companies based in Morris County, New Jersey]]

Pages transcluded onto the current version of this page (help):

Intercept Pharmaceuticals (edit)
Template:Ambox (view source) (template editor protected)
Template:Authority control (view source) (template editor protected)
Template:Cite news (view source) (protected)
Template:Cite web (view source) (protected)
Template:Comma separated entries (view source) (template editor protected)
Template:Coord (view source) (protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Increase (view source) (template editor protected)
Template:Infobox (view source) (template editor protected)
Template:Infobox company (view source) (template editor protected)
Template:Longitem (view source) (template editor protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:NASDAQ was (view source) (semi-protected)
Template:Navbox (view source) (template editor protected)
Template:Official website (view source) (template editor protected)
Template:Pagetype (view source) (protected)
Template:Pharmaceutical companies of the United States (edit)
Template:Reflist (view source) (protected)
Template:Reflist/styles.css (view source) (protected)
Template:SDcat (view source) (protected)
Template:Short description (view source) (protected)
Template:Short description/lowercasecheck (view source) (protected)
Template:Template other (view source) (protected)
Template:URL (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Authority control (view source) (template editor protected)
Module:Authority control/auxiliary (view source) (template editor protected)
Module:Authority control/config (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for clobbered parameters (view source) (template editor protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Coordinates (view source) (protected)
Module:Coordinates/styles.css (view source) (protected)
Module:Disambiguation/templates (view source) (protected)
Module:EditAtWikidata (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Infobox (view source) (template editor protected)
Module:Infobox/styles.css (view source) (template editor protected)
Module:InfoboxImage (view source) (template editor protected)
Module:Math (view source) (protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:Official website (view source) (template editor protected)
Module:Pagetype (view source) (protected)
Module:Pagetype/config (view source) (protected)
Module:Pagetype/disambiguation (view source) (protected)
Module:Pagetype/setindex (view source) (protected)
Module:Pagetype/softredirect (view source) (protected)
Module:SDcat (view source) (protected)
Module:Separated entries (view source) (protected)
Module:String (view source) (protected)
Module:TableTools (view source) (protected)
Module:URL (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:WikidataIB (view source) (template editor protected)
Module:WikidataIB/nolinks (view source) (template editor protected)
Module:WikidataIB/titleformats (view source) (template editor protected)
Module:Wikitext Parsing (view source) (protected)
Module:Yesno (view source) (protected)

Return to Intercept Pharmaceuticals.

Retrieved from "https://en.wikipedia.org/wiki/Intercept_Pharmaceuticals"